|Project name: ||Rotavirus Immunisation Programme - there are 2 reports for this project: 2014, 2015 |
|Google search: ||Google search on project name (opens in new window) |
|Organisation: ||DOH (D12) - see all reports for this organisation |
|Report year: ||2015 (data is from Sept 2014) |
|Category: ||Transformation - see all reports for this category |
|Description: ||Background: Rotavirus infection is the commonest cause of gastroenteritis in children under five years of age worldwide. Rotavirus infection in the UK is seasonal, occurring mostly in winter and early spring. In England and Wales an estimated 130,000 episodes of rotavirus-induced gastroenteritis occurred each year prior to the introduction of immunisation in children less than five years old and approximately 12,700 of these children were hospitalised. In 2011 the Joint Committee on Immunisation and Vaccination (JCVI) advised that the Department of Health should introduce a rotavirus immunisation programme if the vaccine could be procured at a cost effective price. Following negotiations with the manufacturer, the price paid for rotavirus vaccine resulted in the vaccination programme being cost effective.
Objective: The overarching objective of the rotavirus immunisation programme is the reduction of rotavirus-induced gastroenteritis in England.
Scope: The scope of the project is limited to England and includes all the elements required to successfully deliver a rotavirus vaccination programme.
Benefits:: the programme is delivering:
rotavirus immunisation for babies added to the national immunisation schedule;
a reduction of rotavirus-induced gastroenteritis: and
a reduction in the burden on the NHS by reducing hospital admissions and visits to GPs caused by rotavirus-induced gastroenteritis. |
|DCA (RAG): ||Green |
|DCA text: ||The MPA RAG rating was Green at Q2 2014.
The delivery confidence assessment has been set at Green as rotavirus immunisation was successfully introduced on schedule on 1 July 2013. Vaccine uptake is in line with expectations at about 93% for one dose, and about 88% for the full course of two doses. The burden of rotavirus disease has reduced significantly following the introduction of the immunisation programme. Laboratory reports of confirmed instances of rotavirus for the period July 2013 to June 2014 were about 70% lower than the ten-season average for the same period in the seasons 2003/2004 to 2012/2013. This is an early indication, which needs to be confirmed by further investigation, that rotavirus immunisation is having an effect on the level of disease. A GMPP Exit Review was carried out in November 2014 and the Major Projects Authority has decided that this programme should be removed from the GMPP. |
|Start date: ||2009-03-05 |
|End date: ||2014-04-01 |
|Schedule text: ||There have been no deviations from the planned schedule. |
|Baseline: ||£25.50m |
|Forecast: ||£25.50m |
|Variance: ||0.00% |
|Variance text: ||Budget variance less than 5% |
|Whole Life Cost: ||£70.20m |
|WLCost text: ||The budgeted whole life costs (WLC) set out in the Q2 2014/15 GMPP return are estimates from the Full Business Case to implement the programme as a whole, including vaccine purchase costs borne by PHE and vaccine administration costs borne by NHS England. The business case was approved by HM Treasury on 13 August 2012. At that time the programme was planned to start in September 2013. Subsequently it was decided to commence the programme from July 2013, a decision which was agreed with DH Finance. The WLC figure has not changed since the equivalent transparency report in 2013/14. |
|Notes1: || DOH NON CAPITAL |
|Notes2: || |
|Sourcefile: ||IPA_2015.csv |
All Projects (+dates)
All Projects (+costs)
Acknowledgement: GMPP data has been re-used under the Open Government Licence.